Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols"" wg kryterium: Temat


Tytuł:
Low skeletal muscle radiodensity is a risk factor for adjuvant chemotherapy discontinuation in colorectal cancer.
Autorzy:
Yokoi K; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Watanabe A; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Yokota K; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Kojima K; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Tanaka T; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Kojo K; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Miura H; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Yamanashi T; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Sato T; Department of Clinical Skills Education, Research and Development Center for Medical Education, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Yamashita K; Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Kumamoto Y; Department of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Hiki N; Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan.
Naitoh T; Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 252-0374, 1-15-1, Kitasato, Minami-Ku, Sagamihara, Kanagawa, Japan. .
Pokaż więcej
Źródło:
International journal of clinical oncology [Int J Clin Oncol] 2024 Mar; Vol. 29 (3), pp. 276-285. Date of Electronic Publication: 2024 Jan 29.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Colorectal Neoplasms*/pathology
Humans ; Capecitabine/adverse effects ; Oxaliplatin/adverse effects ; Retrospective Studies ; Risk Factors ; Chemotherapy, Adjuvant/adverse effects ; Fluorouracil/adverse effects ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
Autorzy:
Kappel C; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Elliott MJ; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Kumar V; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Nadler MB; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Desnoyers A; Hôpital Charles-Lemoyne, Greenfield Park, QC, Canada.
Amir E; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. .; Princess Margaret Cancer Centre, 610 University Ave, 700U, 7-721, Toronto, ON, M5G 2M9, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 07; Vol. 14 (1), pp. 3129. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Breast Neoplasms*/drug therapy
Female ; Humans ; Aminopyridines ; Benzimidazoles ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Cyclin-Dependent Kinase Inhibitor Proteins ; Neutropenia/chemically induced ; Purines ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study.
Autorzy:
Nishikawa Y; Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
Horimatsu T; Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Oka S; Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan.
Yamada T; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Mitsui K; Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.
Yamamoto H; Department of Medicine, Division of Gastroenterology, Jichi Medical University, Tochigi, Japan.
Takahashi K; Department of Colorectal Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Shiomi A; Division of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Hotta K; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Takeuchi Y; Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Kuwai T; Department of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Ishida F; Digestive Disease Center, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
Kudo SE; Digestive Disease Center, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
Saito S; Department of Lower Gastrointestinal Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Ueno M; Department of Gastroenterological and Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Sunami E; Department of Surgery, Kyorin University School of Medicine, Tokyo, Japan.
Yamano T; Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.
Itabashi M; Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
Ohtsuka K; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Kinugasa Y; Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Matsumoto T; Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Sugai T; Department of Diagnostic Pathology, Iwate Medical University, Iwate, Japan.
Uraoka T; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan.
Kurahara K; Division of Gastroenterology, Matsuyama Red Cross Hospital, Ehime, Japan.
Yamaguchi S; Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
Kato T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Okajima M; Department of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Kashida H; Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
Fujita F; Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan.
Ikematsu H; Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
Ito M; Department of Colorectal Surgery, National Cancer Center Hospital East, Chiba, Japan.
Esaki M; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Kawai M; Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Yao T; Department of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hamada M; Department of Gastrointestinal Surgery, Kansai Medical University Hospital, Osaka, Japan.
Koda K; Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
Fukai Y; Department of Gastroenterology, Maebashi Red Cross Hospital, Gunma, Japan.
Komori K; Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Saitoh Y; Department of Gastroenterology, Asahikawa City Hospital, Asahikawa, Japan.
Kanemitsu Y; Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Takamaru H; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Yamada K; Department of Surgery, Coloproctology Center Takano Hospital, Kumamoto, Japan.
Nozawa H; Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Takayama T; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Togashi K; Department of Coloproctology, Aizu Medical Center Fukushima Medical University, Fukushima, Japan.
Shinto E; Department of Surgery, National Defense Medical College, Tokorozawa, Japan.
Torisu T; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Toyoshima A; Department of Colorectal Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Ohmiya N; Department of Advanced Endoscopy, Fujita Health University School of Medicine, Aichi, Japan.
Kato T; Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Otsuji E; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nagata S; Department of Gastroenterology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
Hashiguchi Y; Department of Surgery, Japanese Red Cross Omori Hospital, Tokyo, Japan.
Sugihara K; Tokyo Medical and Dental University, Tokyo, Japan.
Ajioka Y; Division of Molecular and Diagnostic Pathology Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Tanaka S; JA Onomichi General Hospital, Hiroshima, Japan.
Pokaż więcej
Źródło:
JCO global oncology [JCO Glob Oncol] 2024 Feb; Vol. 10, pp. e2300392.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Adenocarcinoma*/drug therapy
Humans ; Japan ; Intestine, Small/pathology ; Irinotecan/therapeutic use ; Oxaliplatin/therapeutic use
Czasopismo naukowe
Tytuł:
R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study.
Autorzy:
Al-Sarayfi D; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
Brink M; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Chamuleau MED; Department of Hematology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.
Brouwer R; Department of Hematology, Reinier de Graaf Gasthuis, Delft, The Netherlands.
van Rijn RS; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Issa D; Department of Hematology, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands.
Deenik W; Department of Hematology, Rijnstate Hospital, Arnhem, The Netherlands.
Huls G; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
Mous R; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Vermaat JSP; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Diepstra A; Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands.
Zijlstra JM; Department of Hematology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.
van Meerten T; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
Nijland M; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. 216-222. Date of Electronic Publication: 2023 Nov 28.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Lymphoma, Large B-Cell, Diffuse*
Humans ; Aged ; Rituximab ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Vincristine/adverse effects ; Doxorubicin/adverse effects ; Cyclophosphamide ; Prednisone/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy.
Autorzy:
Ermann DA; Department of Hematology/Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Vardell VA; Department of Internal Medicine, University of Utah, Salt Lake City, UT.
Shah H; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT.
Fitzgerald L; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT.
Tao R; Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Gaffney DK; Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Stephens DM; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Hu B; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address: .
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Feb; Vol. 24 (2), pp. 94-104.e6. Date of Electronic Publication: 2023 Oct 10.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/radiotherapy
Humans ; Treatment Outcome ; Retrospective Studies ; Multivariate Analysis ; Prognosis
Czasopismo naukowe
Tytuł:
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape.
Autorzy:
Al-Antary ET; Division of Hematology/Oncology, Children's Hospital of Michigan, Pediatric Blood and Marrow Transplantation Program, Barbara Ann Karmanos Cancer Center, Detroit, MI, USA. .; Department of Pediatrics, Central Michigan University College of Medicine, Mt Clemons, MI, USA. .
Gupte A; Division of Hematology/Oncology, Children's Hospital of Michigan, Pediatric Blood and Marrow Transplantation Program, Barbara Ann Karmanos Cancer Center, Detroit, MI, USA.; Department of Pediatrics, Central Michigan University College of Medicine, Mt Clemons, MI, USA.
Ravindranath Y; Division of Hematology/Oncology, Children's Hospital of Michigan, Pediatric Blood and Marrow Transplantation Program, Barbara Ann Karmanos Cancer Center, Detroit, MI, USA.; Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI, USA.
Pokaż więcej
Źródło:
Indian journal of pediatrics [Indian J Pediatr] 2024 Feb; Vol. 91 (2), pp. 176-183. Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Child ; Humans ; Cytarabine/therapeutic use ; Recurrence ; Anthracyclines/therapeutic use
Czasopismo naukowe
Tytuł:
Long-term Survivor of Unresectable Pancreatic Cancer Treated with Concurrent Chemoradiotherapy.
Autorzy:
Song YJ; Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.
Choi JH; Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.
Pokaż więcej
Źródło:
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi [Korean J Gastroenterol] 2024 Jan 25; Vol. 83 (1), pp. 28-32.
Typ publikacji:
Case Reports
MeSH Terms:
Adenocarcinoma*/diagnosis
Adenocarcinoma*/therapy
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Pancreatic Neoplasms*/diagnosis
Pancreatic Neoplasms*/therapy
Adult ; Humans ; Male ; Chemoradiotherapy ; Positron Emission Tomography Computed Tomography ; Survivors ; Cancer Survivors
Raport
Tytuł:
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Autorzy:
Zhong Q; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian Provincial Key Laboratory of Translational Cancer Medicine, 420 Fuma Road, Fuzhou, 350014, China.; Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, China.
Chen H; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Chen D; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Road, Fuzhou, 350014, China.
Qin Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
He X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Yang Y; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Road, Fuzhou, 350014, China.
Yang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Liu P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhou S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Yang S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhou Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Tang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Chen C; Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Road, Fuzhou, 350014, China. .
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 211-226. Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*/pathology
Humans ; Rituximab/therapeutic use ; Survival Rate ; Retrospective Studies ; Prognosis ; Cohort Studies ; Cyclophosphamide/therapeutic use ; Prednisone/therapeutic use ; Vincristine/therapeutic use ; Doxorubicin/therapeutic use ; Risk Assessment
Czasopismo naukowe
Tytuł:
Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer.
Autorzy:
Krishnan S; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Center, 14 Major Arterial Road (East-West), Newtown, Rajarhat, Kolkata, West Bengal, 700160, India. .; Department of Pediatric Hematology and Oncology, Tata Medical Center, Kolkata, India. .; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, UK. .
Mahadevan A; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Center, 14 Major Arterial Road (East-West), Newtown, Rajarhat, Kolkata, West Bengal, 700160, India.
Mungle T; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Center, 14 Major Arterial Road (East-West), Newtown, Rajarhat, Kolkata, West Bengal, 700160, India.
Gogoi MP; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Center, 14 Major Arterial Road (East-West), Newtown, Rajarhat, Kolkata, West Bengal, 700160, India.
Saha V; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Center, 14 Major Arterial Road (East-West), Newtown, Rajarhat, Kolkata, West Bengal, 700160, India.; Department of Pediatric Hematology and Oncology, Tata Medical Center, Kolkata, India.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, UK.
Pokaż więcej
Źródło:
Indian journal of pediatrics [Indian J Pediatr] 2024 Jan; Vol. 91 (1), pp. 47-58. Date of Electronic Publication: 2023 Jul 26.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Child ; Humans ; Mercaptopurine/therapeutic use ; Methotrexate/therapeutic use
Czasopismo naukowe
Tytuł:
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital.
Autorzy:
Li S; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Sharma B; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Yusuf S; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Michalarea V; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Gleeson M; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Hickmott L; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Wotherspoon A; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Attygalle AD; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Vroobel K; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
O'Connor S; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Du Y; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Kuhnl A; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Iyengar S; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
El-Sharkawi D; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Chau I; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom.
Cunningham D; Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom. Electronic address: .
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jan; Vol. 24 (1), pp. 48-54. Date of Electronic Publication: 2023 Aug 29.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Rituximab/therapeutic use ; Retrospective Studies ; Positron-Emission Tomography/methods ; Cyclophosphamide/therapeutic use ; Vincristine/adverse effects ; Prednisone/adverse effects ; Doxorubicin/adverse effects
Czasopismo naukowe
Tytuł:
Drug combinations screening using a Bayesian ranking approach based on dose-response models.
Autorzy:
Boumendil L; Université Paris Cité, INSERM U1153, Team ECSTRRA, Paris, France.
Fontaine M; Université Paris Cité, Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, Paris, France.
Lévy V; Université Paris Cité, INSERM U1153, Team ECSTRRA, Paris, France.; Sorbonne Paris Nord, Unité de Recherche Clinique, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France.
Pacchiardi K; Université Paris Cité, Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, Paris, France.; Laboratoire d'Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Itzykson R; Université Paris Cité, Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, Paris, France.; Service Hématologie Adultes, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Biard L; Université Paris Cité, INSERM U1153, Team ECSTRRA, Paris, France.; Service de Biostatistique et Information Médicale, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Pokaż więcej
Źródło:
Biometrical journal. Biometrische Zeitschrift [Biom J] 2024 Jan; Vol. 66 (1), pp. e2200332. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*
Neoplasms*/drug therapy
Humans ; Bayes Theorem ; Drug Combinations ; Research Design ; Sample Size ; Dose-Response Relationship, Drug
Czasopismo naukowe
Tytuł:
Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Autorzy:
Fujimura T; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Yoshino K; Department of Dermato-Oncology/Dermatology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Nakamura M; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kato H; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Ito T; Department of Dermatology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Maekawa T; Department of Dermatology, Jichi Medical University Saitama Medical Center, Shimotsuke, Japan.
Fujisawa Y; Department of Dermatology, Ehime University, Matsuyama, Japan.
Matsushita S; Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.
Amagai R; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Yamazaki E; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Takahashi M; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Tamabuchi E; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Hashimoto A; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Kambayashi Y; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Miyata T; Department of Molecular Medicine and Therapy, Tohoku University School of Medicine, Sendai, Japan.
Asano Y; Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
Pokaż więcej
Źródło:
Experimental dermatology [Exp Dermatol] 2024 Jan; Vol. 33 (1), pp. e14976. Date of Electronic Publication: 2023 Nov 09.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Hemangiosarcoma*/drug therapy
Skin Neoplasms*/drug therapy
Humans ; Clinical Trials, Phase II as Topic ; Endothelial Cells ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Plasminogen Activator Inhibitor 1 ; Multicenter Studies as Topic
Czasopismo naukowe
Tytuł:
Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.
Autorzy:
Locke M; Department of Internal Medicine, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York, USA.
Kohn N; Office of Academic Affairs, Northwell Health, Manhasset, New York, USA.
Seetharamu N; Monter Cancer Center, Northwell Health, Manhasset, New York, USA.
Pokaż więcej
Źródło:
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery [Clin Otolaryngol] 2023 Nov; Vol. 48 (6), pp. 915-919. Date of Electronic Publication: 2023 Jul 30.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/administration & dosage
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/pathology
Head and Neck Neoplasms*/surgery
Squamous Cell Carcinoma of Head and Neck*/drug therapy
Squamous Cell Carcinoma of Head and Neck*/pathology
Squamous Cell Carcinoma of Head and Neck*/surgery
Humans ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Cetuximab/administration & dosage ; Cetuximab/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/prevention & control ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Guiding model-driven combination dose selection using multi-objective synergy optimization.
Autorzy:
Gevertz JL; Department of Mathematics and Statistics, The College of New Jersey, Ewing, New Jersey, USA.
Kareva I; Quantitative Pharmacology Department, EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1698-1713. Date of Electronic Publication: 2023 Jul 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/pharmacology
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Algorithms*
Humans ; Drug Synergism ; Combined Modality Therapy ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.
Autorzy:
Guo Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Guo D; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Kong D; Department of Hematology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Bian S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Lin L; Department of Hematology, Yantai Yuhuangding Hospital, Qingdao University Medical College, Yantai, People's Republic of China.
Fan S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Q; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Zhao Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Jiang Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yan J; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Wang Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Sun L; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2219930.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Azacitidine*/adverse effects
Histone Deacetylase Inhibitors*/adverse effects
Leukemia, Myeloid, Acute*/metabolism
Antimetabolites, Antineoplastic*/adverse effects
Adult ; Humans ; Cytarabine/therapeutic use ; Decitabine/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor.
Autorzy:
Weng P; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Yang S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Xu S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Zhang S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Wu Y; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Chen Y; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2220521.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Leukemia, Myeloid, Acute*
Humans ; Prognosis ; Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects ; Leukocytes ; Granulocyte Colony-Stimulating Factor/therapeutic use
Czasopismo naukowe
Tytuł:
Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP.
Autorzy:
Ma'koseh M; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Farfoura H; Department of Radiology, King Hussein Cancer Center, Amman, Jordan.
Abufara A; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Elmusa R; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Hushki A; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Faqeer N; Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan.
Ghatasheh H; Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
Shahin O; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Alawabdeh T; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Al-Rwashdeh M; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Halahleh K; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Al-Ibraheem A; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Alrabi K; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2198898.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*
Humans ; Disease-Free Survival ; Prednisone ; Rituximab/therapeutic use ; Cyclophosphamide ; Vincristine ; Doxorubicin ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Autorzy:
Tarlock K; Department of Pediatrics, Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Liu X; Children's Oncology Group, Monrovia, California, USA.
Minard CG; Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
Isikwei EA; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Reid JM; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Horton TM; Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Fox E; Cancer Center, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Weigel BJ; Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Cooper T; Department of Pediatrics, Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Dec; Vol. 70 (12), pp. e30672. Date of Electronic Publication: 2023 Sep 14.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Cyclopentanes*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Pyrimidines*/therapeutic use
Adolescent ; Adult ; Child ; Child, Preschool ; Humans ; Infant ; Young Adult ; Azacitidine/therapeutic use ; Chronic Disease ; Cytarabine/therapeutic use ; Feasibility Studies ; Myelodysplastic Syndromes/drug therapy ; Vidarabine/analogs & derivatives
Czasopismo naukowe
Tytuł:
Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Autorzy:
Sutter T; Department of Oncology and Hematology, Cantonal Hospital St Gallen, Zürich, Switzerland.
Schittenhelm M; Department of Oncology and Hematology, Cantonal Hospital St Gallen, Zürich, Switzerland.
Volken T; ZHAW School of Health Sciences, Institute of Public Health, Winterthur, Switzerland.
Lehmann T; Department of Oncology and Hematology, Cantonal Hospital St Gallen, Zürich, Switzerland.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2206694. Date of Electronic Publication: 2023 May 11.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/diagnosis
Humans ; Middle Aged ; Retrospective Studies ; Proto-Oncogene Proteins c-bcl-2/therapeutic use
Czasopismo naukowe
Tytuł:
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Autorzy:
Jerusalem G; Medical Oncology Department, CHU Sart Tilman and Liège University, Domaine Universitaire, B35, 4000, Liège, Belgium. Electronic address: .
Prat A; Department of Medicine, University of Barcelona, Hospital Clinic, IDIBAPS, c/ Rosselló, 149-153, 08036, Barcelona, Spain. Electronic address: .
Salgado R; GZA-ZNA Hospitals, Oosterveldlaan 24, 2610, Antwerp, Belgium. Electronic address: .
Reinisch M; Breast Unit Kliniken Essen-Mitte, Henricistrasse 40, 45136, Essen, Germany; Department of Gynecology with Breast Center Charité, Charitéplatz 1, 10117, Berlin, Germany. Electronic address: .
Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Centro Cellex, Carrer de Natzaret, 115, 117, 08035, Barcelona, Spain. Electronic address: .
Ruiz-Borrego M; Virgen del Rocío University Hospital, Av. Manuel Siurot, S/n, 41013, Sevilla, Spain. Electronic address: .
Nikolinakos P; University Cancer and Blood Center, 3320 Old Jefferson Rd, Bldg 700, Athens, GA, 30607, USA. Electronic address: .
Ades F; Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, Princeton, NJ, USA. Electronic address: .
Filian J; Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, Princeton, NJ, USA. Electronic address: .
Huang N; Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, Princeton, NJ, USA. Electronic address: .
Mazzei-Abba A; Bristol Myers Squibb, Rte de Perreux 1, 2017, Boudry, Switzerland. Electronic address: .
Tolaney SM; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. Electronic address: sara_.
Pokaż więcej
Źródło:
Breast (Edinburgh, Scotland) [Breast] 2023 Dec; Vol. 72, pp. 103580. Date of Electronic Publication: 2023 Sep 15.
Typ publikacji:
Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Breast Neoplasms*/drug therapy
Female ; Humans ; Anastrozole ; Neoadjuvant Therapy ; Nivolumab ; Pneumonia ; Receptor, ErbB-2 ; Receptors, Estrogen
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies